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Abstract
Background Conjugation of anti-neoplastic agents with hu-
man proteins is a strategy to diminish the toxic side effects of
anthracycline antibiotics. We have developed a novel
doxorubicin-transferrin (DOX-TRF) conjugate aimed to di-
rect anticancer drugs against therapeutic targets that display
altered levels of expression in malignant versus normal cells.
Our previous work has shown that the cellular bio-distribution
of the conjugate is dependent on a dynamic balance between
influx and efflux processes. Here, we set out to investigate
whether P-glycoprotein (P-gp) expression may affect DOX-
TRF conjugate-induced cellular drug accumulation and
cytotoxicity.
Results All experiments were carried out on human
erythromyeloblastoid cells exhibiting P-gp over-expression
(K562/DOX) and its drug sensitive parental line (K562).
MTT cytotoxicity, flow cytometry, fluorescence microscopy
and RT-PCR assessments revealed that the investigated con-
jugate (DOX-TRF) possesses a greater cytotoxic potential
than free DOX.
Conclusion Our data suggest that the newly developed DOX-
TRF conjugate is a less P-gp dependent substrate than free
DOX and, consequently, may be used in a clinical setting to
increase treatment efficacy in resistant human tumors.
Keywords Doxorubicin . Transferrin . Drug carriers .
Multidrug resistance . P-glycoprotein
1 Introduction
Anthracyclines represent an important class of anti-neoplastic
agents that are active against a variety of hematologic [1, 2]
and solid [3, 4] tumors. However, the clinical effectiveness of
anthracyclines is often restricted by dose-limiting cardiac
toxicity and myelosuppression [5]. The toxicity of doxorubi-
cin (DOX), which belongs to these antrachinone antibiotics, is
connected to the apoptosis of cancer cells by a complex
network of events, which includes intercalation into DNA,
generation of reactive oxygen species, topoisomerase II inhi-
bition and DNA damage [6]. However, successful anticancer
chemotherapy through the application of DOX requires a
sufficient number of molecules enabling DOX to be delivered
to the neoplastic cells while sparing normal cells. Attaching
anthracycline antibiotic polymers, and especially tumor-
associated antigens, has long been envisioned as a means to
more selectively delivering chemotherapeutic agents [7].
Thus, DOX is often loaded to various polymeric or natural
hydrogels, including poly(organophosphazene), liposomes,
dendrimers, nanoparticles and antibodies [8], or even human
serum proteins. Among these serum proteins, serum albumin
and transferrin (TRF) have gained most interest due to their
potential as drug delivery systems for improving cancer che-
motherapy. These proteins are biodegradable, non-toxic, non-
immunogenic and exhibit a preferential uptake in tumor tissue
[9]. In addition, protein conjugates can accumulate in solid
tumors due to the frequently enhanced microvasculature of
tumor tissues [10, 11]. This phenomenon has been termed
enhanced permeability and retention in relation to tumor
targeting (‘EPR-phenomenon’) [12].
Several studies have shown the potential of TRF in the
delivery of anticancer drugs to malignant cells that over-
express TRF receptors [9]. TRF can covalently be linked to
DOX (i.e., DOX-TRF) via a Shiff base which is formed by
using glutaraldehyde. This bond was found to be stable at a
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physiological pH of 7.4 and is not affected by endogenous
human enzymes [12]. Inside the cells, DOX is quickly released
from the conjugate at pH 5 in endosomes or lysosomes [13].
One of the major factors that causes a pressing need to find
a way to deliver anticancer drugs directly to neoplastic cells is
the rapid emergence of drug resistant cell populations related
to over-expression of ATP-binding cassette (ABC) proteins
[14]. P-glycoprotein/MDR1 (P-gp) is a 170-kDa membrane
transporter glycoprotein encoded by the ABCB1 gene. It is
known that in patients with breast cancer P-gp expression is a
leading cause of resistance to chemotherapy [15]. P-gp is also
expressed in other cancer cells and normal tissues under
physiological conditions, indicating its major role in the cel-
lular transport of various endogenous substrates and therapeu-
tic agents [16, 17]. Over-expression of P-gp results in an
active efflux of anticancer agents from cells and, consequent-
ly, a reduction of intracellular drug concentrations and an
increased resistance of cancer cells to chemotherapeutic drugs,
especially substrate anti-cancer drugs [18, 19]. At present,
more than 100 compounds have been identified as P-gp sub-
strates, and one of them is free DOX [20].
Here, we aimed to investigate whether DOX-TRF can
impair the role of the P-gp transport system and, if so, what
the connection is between this functionality and the cytotox-
icity of DOX-TRF. Our experiments were carried out in the
absence and presence of the P-gp inhibitor Cyclosporin A
(CsA) in chronic erythromyeloblastoid leukemia cells sensi-
tive (K562) and resistant (K562/DOX) to doxorubicin. We
found that the investigated cells exhibit different sensitivities
to the conjugate. Using flow-cytometry and fluorescence mi-
croscopy, we observed alterations in Rhodamine 123 (R123)
accumulation in K562 and K562/DOX cells. Moreover, by
assessment ofABCB1 gene expression at the mRNA (RT-PCR
assay) and protein (MDR-1 shift assay) levels, we observed
different time- and concentration-dependent effects of free
DOX and DOX-TRF.
2 Materials and methods
2.1 Chemical products
Doxorubicin (DOX) was obtained from Sequoia Research
Products (Pangbourne, UK). RPMI 1640 bicarbonate was
supplied by Cambrex (Basel, Switzerland). Fetal bovine se-
rum (FBS), penicillin and streptomycin were purchased from
PAA (Edinburgh, Scotland). R123, Cyclosporin A and mate-
rials for carrying out the conjugation procedure were pur-
chased from Sigma (Darmstadt, Germany). DOXwas coupled
to TRF using a modified conjugation procedure developed by
Berczi et al. [21]. Subsequently, the integrity of the obtained
DOX-TRF conjugate was analyzed by mass spectrometry
[22]. All other chemicals and solvents were of high analytical
grade and were obtained from Sigma (Germany) or POCH
S.A. (Gliwice, Poland).
2.2 Cell culture
Chronic erythromyeloblastoid leukemia cells sensitive (K562)
and resistant (K562/DOX) to DOXwere a kind gift from Prof.
J. Robert, Institute Bergonie, France. Cells were grown in
75 cm2 tissue culture flasks and cultured in RPMI 1640
bicarbonate medium supplemented with 10 % fetal bovine
serum (FBS), 100 units/ml penicillin, and 100 μg/ml strepto-
mycin (PAA, Germany). Cultures were maintained at 37 °C in
a humidified atmosphere (5 % CO2). K562/DOX cells were
grown in the same medium as the parental K562 cells, sup-
plemented with 0.02 μM DOX [23]. Cells were plated in 96-
well plates (10,000 cells/well) for cytotoxicity, proliferation
and mitochondrial membrane potential assays, and in 6-well
plates (100,000 cells/well) for flow cytometry, real-time PCR
and MDR-1 protein shift assays. Cells were allowed to grow
24 h before treatment and the cultures were monitored
periodically for Mycoplasma contamination.
2.3 Growth inhibition assay
The effect of the DOX-TRF conjugate or free DOX on K562
and K562/DOX cell growth was determined using a MTT dye
(3-(4,5-dmethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay in 96-well microtiter plates with flat-bottomed
wells (Nunc, Denmark) in a total volume of 100 μl. Cells
subcultured at a density of 1x104 were incubated with various
concentrations of the DOX-TRF conjugate or free DOX at
37 °C for 72 h. Subsequent to treatment with free DOX or its
conjugate, MTT (Sigma) at a final concentration of 0.5 mg/ml
was added to each culture well. The dark colored crystals
produced by viable cells were solubilized with 30 mM HCl
in 2-propanol. The absorbance was determined at 570 nm
using a microplate reader (Awareness Technology Inc.,
USA). The drug concentration required for 50 % growth
inhibition (IC50) of leukemia cells was determined from the
corresponding dose–response curves. In order to examine the
effect of Cyclosporin A (CsA) on the cytotoxicity of the
DOX-TRF conjugate or free DOX, the cells were pre-
incubated with this P-gp inhibitor (30 μM) for 30 min. The
CsA dose concentration was evaluated during assessment of
its toxicity on the viability of the tested cells.
2.4 Assessment of P-gp activity
For assessment of the activity of P-gp as a transporter across
cellular membranes we used Rhodamine 123 (R123). Based
on the fact that R123’s intracellular concentration depends on
the activity of this transmembrane efflux protein, this fluores-
cence probe has amply been used for the analysis of P-gp
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activity. The experiments were carried out according the fol-
lowing procedure. Cells seeded in Petri dishes at a density
1×106 cells/ml were pre-incubated without or with 30 μM
CsA for 30min at 37 °C in culture medium. Then free DOX or
DOX-TRF at an IC50 concentration was added and the sam-
ples were further incubated for 24 h. Subsequently, the culture
medium was removed, and the cells were washed twice with
PBS and removed from the culture dishes. After centrifuga-
tion (300×g for 10 min at 4 °C), the cells were re-suspended in
ice-cold PBS, and to all samples 50 μl R123 was added to a
final concentration of 0.1 M. The cellular uptake of
R123 was monitored per 20 min on a flow cytometer (BD
Immunocytometry Systems, San Jose, USA), equipped with a
488 nm argon laser and 2 fluorescence detectors: FL1 and
FL2. Finally, fluorescence of the analyzed samples after incu-
bation with R123 was evaluated using a fluorescence micro-
scope (Olympus XI-70, Tokyo, Japan) at excitation and emis-
sion wavelengths of 497 nm and 520 nm, respectively.
2.5 ABCB1 gene expression analysis
1x105 cells were seeded per well in a 6-well plate and cultured
with an IC50 concentration of the examined compounds for
48 h. Total RNA from the cells was extracted using TRI
Reagent (Sigma, Germany) according to the manufacturer’s
instructions. The RNA concentrations were quantified using
an UV spectrophotometer (NanoDrop ND-1000 Spectropho-
tometer, Thermo Scientific, USA). Then cDNA was synthe-
sized from equal amounts of RNA using a Maxima First
Strand cDNA Synthesis Kit for RT-PCR (Thermo Scientific,
USA). The primer sequences used were as follows: ERK1
GenBank: ABCB1 forward, 5′-TGGAAACAGTGGCTGT
GGGAAG-3′, and reverse, 5′-TCCTGTCCATCAACACTG
ACCATC-3′; HMBS GenBank: NM_002745 forward, 5′-
GGCAATGCGGCTGCAA-3′, and reverse, 5′-GGGTACCC
ACGCGAATCAC-3′; HPRT1 GenBank: NM_001101 for-
ward, 5′-TGACACTGGCAAAACAATGCA -3′, and reverse,
5′-GGTCCTTTTCACCAGCAAGCT-3′. The expression
levels of the different genes were measured by real-time PCR
amplification in conjunction with a SYBR Green I Master Mix
(Roche) using a LightCycler 480 (Roche, Basel, Switzerland).
Finally, threshold cycle numbers (Ct) were used to calculate the
expression of each target gene by normalizing to the house-
keeping genes hydroxymethylbilane synthase (HMBS) and
hypoxanthine phosphoribosyltransferase 1 (HPRT1).
2.6 MDR-1 shift assay
Conformational changes in P-gp protein that occur as a result
of transporting MDR1 substrates into K562 and K562/DOX
cells were evaluated using a R-phycoerythrin (R-PE)-
conjugated mouse anti-human P-gp monoclonal antibody
(UIC2; Millipore, USA) according to the MDR Shift assay
protocol [24]. This assay allowed us to determine to what
extent which molecules (DOX or DOX-TRF) act as MDR1
substrates for P-gp. Because UIC2 binding increases in the
presence of MDR1 substrates, we utilized this assay for a
highly sensitive and specific detection of P-gp expression.
After a 48 h incubation with free DOX or DOX-TRF, cells
were collected, washed twice with PBS, and incubated for
15 min at 37 °C with R-PE conjugated anti-human P-gp
monoclonal antibody UIC2 (UIC2 PE). After a 15 min incu-
bation at 4 °C, the cells were washed twice with PBS and kept
on ice until measurements. As a positive control vinblastine-
treated cells were used. Measurements were performed on a
flow cytometer using the FL2 channel (BD Immunocytometry
Systems, San Jose, USA see above).
2.7 Statistical analyses
Data were expressed as a means ± S.D. Evaluation of the
distribution normality of the investigated variables was per-
formed by a Shapiro-Wilk test, and homogeneity of variance
was evaluated using Levene’s test. In order to assess statisti-
cally significant differences between the studied variables, we
performed a multivariate analysis of variance (ANOVA), and
Tukey’s test was used for post-hoc analyses [25]. All statistics
were calculated using the STATISTICA program version 11
(StatSoft, Tulsa, OK, USA). A p-value of <0.05 was consid-
ered significant.
3 Results
3.1 Increased cytotoxicity of the DOX-TRF conjugate
To study the effect of free DOX or DOX conjugated with TRF
on sensitive and resistant K562 cells, we carried out a MTT
assay. As shown in Fig. 1, a statistically significant reduction in
the amount of formazan forming cells in the presence of the
examined drugs (DOX or DOX-TRF) was found to be concen-
tration-dependent. However, when the cells were treated with
DOX-TRF, the fraction of surviving cells decreased more sig-
nificantly, both inK562 andK562/DOXcells, compared to those
treated with free DOX. The IC50 values (indicating the concen-
tration that provides 50 % cell survival after a 72 h incubation
period) for the drugs studied were as follows: in K562 cells
263.0±6.2 nM for DOX, 70.3±4.6 nM for DOX-TRF, and in
K562/DOX cells 2814.0±33.4 nM for DOX, 278.4±1.4 nM for
DOX-TRF. An additional variant of the experiment was the
assessment of viability after exposure of the cells for 72 h to
CsA at a 0.5–50 μM concentration range. We noticed that the
effect of different concentrations of CsA was not statistically
significant, and that the survival of cells treated with this P-gp
inhibitor did not decrease below 90 % (data not shown).
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Therefore, we decided to use a 30 μM concentration of CsA,
which is in conformity with literature data [26, 27]. In cells pre-
incubated with this CsA concentration and, subsequently, treated
with free DOX or DOX-TRF, we observed an increased cyto-
toxicity of both DOX and DOX-TRF (Fig. 1). In K562 and
K562/DOX cells treated with free DOX, CsA reduced the
survival with about 25 %. A similar reduction in survival was
obtained in DOX-TRF treated cells. No statistically significant
difference was noted between the two.
3.2 DOX and its conjugate modify the functionality of P-gp
Next, we set out to examine the effect of free DOX and DOX-
TRF on P-gp activity by measuring the intracellular accumula-
tion of Rhodamine 123 (R123). The results obtained were
compared to those of positive controls, i.e., CsA pre-treated
cells. Based on the curves presented in Fig. 2a, fluorescence
ratios were calculated for each tested probe. A markedly higher
accumulation of fluorescence probes was observed in K562/
DOX cells, even though these cells are resistant to DOX
(Fig. 2b). In these cells, free DOX was found to increase the
R123 cellular influx (1.72±0.14) in a much more noticeable
way than DOX-TRF (1.29±0.13). The relative assessment of
P-gp activity obtained from the cytometric analysis in DOX-
sensitive K562 cells confirmed that both free DOX and its
conjugate modify the functionality of P-gp. We found that the
investigated compounds can increase the accumulation of R123
by factors of 1.38 and 1.16, respectively, compared to control
samples without drugs and CsA pre-treatment. These results,
obtained by flow cytometry, were subsequently confirmed by
fluorescence microscopy (Fig. 3). We noticed a maximal R123
accumulation in K562/DOX cells pre-treated with CsA. How-
ever, when we compared the fluorescence intensity in cells
incubated with free DOX or DOX-TRF, we observed a higher
R123 accumulation in cells treated with the free drug.
3.3 DOX increases ABCB1 transcription in K562
and K562/DOX cells
To assess the role of free DOX and DOX-TRF in P-gp expres-
sion, we measured ABCB1 transcript levels (relative to HBMS
and HPRT1) in parental K562 cells and its resistant derivative
K562/DOX. RT-PCR analyses revealed that the mRNA ex-
pression level was higher in control, untreated K562/DOX
cells (318.9) than in K562 sensitive cells (146.8) (Fig. 4).
When cells were treated with free DOX, we observed a statis-
tically higher ABCB1 transcript level (#) compared to cells
incubated with DOX-TRF. Free DOX induced an increase in
ABCB1 transcription of 6.2 and 1.7 times in K562 and K562/
DOX cells, respectively, whereas the same cells treated with
DOX-TRF showed increases in ABCB1 mRNA expression
levels of 1.6 and 1.3 times, respectively. As shown in Fig. 4,
pre-incubation of the cells with CsA decreased the ABCB1
transcript levels in both investigated cell types treated with
either free DOX or TRF-conjugated DOX.
3.4 Changes in P-gp expression after DOX or DOX-TRF
treatment
In Fig. 5 changes in P-gp expression are presented after
treatment of the cells with free DOX or DOX-TRF. Using
monoclonal antibody UIC2 (see section 2), we detected a 3
times higher level of P-gp in K562/DOX cells (7.2 %) than in
the parental cell line K562 (2.4 %). In cells exposed to the
examined compounds, the highest P-gp changes were found
in DOX-treated K562/DOX cells (30 % increase relative to
Fig. 1 Representative dose–
response curves following
exposure to DOX and DOX-TRF
conjugate of K562 cells sensitive
and resistant (K562/DOX) to
doxorubicin. The evaluation of cell
survival was assessed by MTT
assay. ∗p<0.05, significant effects
of the examined compounds on
the viability of human leukemia
cells. #p<0.05, significant changes
between the probes preincubated
with Cyclosporin A (CsA).
The values are the mean ± SD
of four independent experiments
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control, untreated cells). Also, DOX-TRF was found to pro-
voke an increase in P-gp change in both cell lines tested, but to
a significantly (#) lesser extent than the free drug. Pre-
treatment of the cells with CsA indicated that free DOX causes
higher changes in P-gp expression than the DOX-TRF conju-
gate. Vinblastine, which we used as a positive control, con-
firmed that the expression of P-gp was 2.6 times higher in the
K562 cell line resistant to DOX compared to the parental line.
4 Discussion
The objective of this study was to test whether the application
of a doxorubicin-transferrin (DOX-TRF) conjugate can
Fig. 2 Uptake of R123 in the presence of Cyclosporin A (CsA), DOX or
DOX-TRF by K562 sensitive and resistant (K562/DOX) cells as a
function of time (A). The values are the means ± SD of three independent
experiments. Additionally, on the basis of fluorescence ratios of R123
transport by the examined cell lines, we calculated P-gp functional
activities as the slopes of the obtained curves (B). ∗p<0.05, significant
differences between P-gp functional activity calculated from the influx of
R123 or R123 plus CsA and from R123 plus DOX or DOX-TRF after a
20-min period of monitoring the transport of fluorescence probe to the
cells. +p<0.05, significant differences between positive control samples
(cells pre-incubated with CsA) and cells treated with DOX or DOX-TRF.
#p<0.05, significant differences between cells treated with free DOX
or DOX-TRF
Fig. 3 Intracellular R123 accumulation in K562 cells sensitive and
resistant (K562/DOX) to doxorubicin. The cells were incubated with IC50
concentrations of free DOX or DOX-TRF for 24 h. In the experiments with
Cyclosporin A (CsA) the cells were preincubated for 20 min at 37 °C and
then incubated with drugs. Fluorescence was monitored using an Olympus
IX70 microscope (Japan), magnification 400×
Fig. 4 ABCB1 transcript levels (relative to housekeeping genes) in K562
sensitive and resistant (K562/DOX) cells exposed to free DOXorDOX-TRF
for 48 h. Asterisks refer to significant differences (*p<0.05, n=3) in
expression levels in cells treated with the investigated compounds compared
to untreated cells, whereas hashes (#p<0.05, n=3) relate to significant
differences observed between the cells treated with DOX or DOX-TRF
Relationship between therapeutic efficacy 425
effectively overcome P-glycoprotein (P-gp) related drug re-
sistance and, thus, improve the efficacy of anticancer therapy.
Therefore, we compared the activity, transcription and expres-
sion of P-gp in erythromyeloblastoid cells treated with free
DOX or DOX-TRF. Our experiments, aimed to assess these
various parameters, were carried out in parallel with an eval-
uation of the cytotoxicity of the investigated anticancer com-
pounds. The cell-killing effects of free DOX and the DOX-
TRF conjugate were also tested in combination with a P-gp
inhibitor, Cyclosporin A (CsA). Our findings are in agreement
with those of Lo et al. [28], who indicated that in a non-small
cell lung cancer cell line (A549) some anthracyclines and their
derivatives, like aclarubicin, modulate the functionality of P-
gp. We also showed that the combination of free DOX plus
CsA was more cytotoxic to the investigated leukemia cells
than any of the agents used individually. Moreover, we ob-
served an increase in DOX-TRF conjugate cytotoxicity in
K562/DOX cells more significantly than in DOX-sensitive
K562 cells. Literature data indicate that conjugation of anti-
cancer drugs with nano-sized delivery systems can be obtain-
ed with dendrimers, nanoparticles, micelles [29–31] and plas-
ma proteins. These potential carriers, when conjugated with
hydrophobic drugs, can increase their cumulative dose and
improve their accumulation in the tumor microenvironment
over time [32, 33]. Recently, a linkage of TRF to liposomal
DOX containing verapamil (VER), i.e., Tf-L-DOX/VER, has
been obtained and shown to be able to overcome multi-drug
resistance (MDR) [34]. In addition, targeted liposomal deliv-
ery has been shown to increase tumor cell-selective cytotox-
icity and to facilitate P-gp bypass andMDR reversal. Wu et al.
[34] confirmed that TRF-targeted liposomal delivery of co-
encapsulated DOX and VER (L-DOX/VER) can be an effec-
tive strategy to selectively target and reverse drug resistance in
K562 cells. Moreover, these results showed that Tf-L-DOX/
VER exhibited an approximately 5 times lower IC50 value
than that of non-targeted L-DOX/VER. To test the hypothesis
whether the higher toxicity of the DOX-TRF conjugate may
be a result of its lower exclusion from cells by P-gp related
transport, we used R123, which is a known substrate for P-gp,
and evaluated the effect of free DOX and conjugated DOX-
TRF on its intracellular transport. An increase in P-gp activity
was observed in both sensitive and resistant K562 cells incu-
bated with DOX. Our work also indicates that the DOX-TRF
conjugate does not modulate the functionality of P-gp, espe-
cially in K562/DOX cells. Our flow cytometric data were in
agreement with subsequent microscopic observations of R123
accumulation in cells treated with free DOX or the DOX-TRF
conjugate, i.e., after 20 min incubation of the cells with R123
we noted a higher fluorescence intensity in cells incubated
with conjugated DOX than in those incubated with free DOX.
As yet, the effects of drugs conjugated with human plasma
proteins on P-gp activity are still controversial. The anti-tumor
effect of the DOX-TRF conjugate, which is readily internal-
ized into drug-resistant cells, has been attributed to a direct
binding to P-gp [35]. As far as we know, a higher activity of P-
gp is related to conformational changes that occur upon trans-
port of MDR1 substrates. This notion was underscored by
comparing conformational changes that occur after treatment
with free DOX or DOX-TRF, i.e., by carrying out a MDR1
shift assay we found that UIC2 antibody binding was drasti-
cally increased in the presence of free DOX, whereas DOX-
TRF caused less detectable conformational changes in P-gp.
Also, CsA pre-treatment appeared to confirm that P-gp is
critical for the efflux of both free DOX and DOX-TRF,
although with different kinetics and affinities. Interestingly,
these results were in keeping with ABCB1 transcript levels
assessed by real-time PCR, performed after 48 h incubation
with the investigated compounds. In the past, the impact of
ATP-binding cassette transporters such as P-gp in mediating
multi-drug resistance in chronic erythromyeloblastoid
leukemia cells has been reported [36]. We found that
transcription of the multi-drug resistance ABCB1 gene
in K562/DOX cells was about 3-fold higher than that
in the parental DOX-sensitive cell line K562. Moreover,
we found that free DOX treatment causes a more signif-
icant increase in ABCB1 gene transcription than the
DOX-TRF conjugate. In P-gp over-expressing K562 cells
the increase of DOX-TRF-induced ABCB1 transcription
was not statistically significant.
In summary, we here show that there is a relationship
between an increased cytotoxicity of the DOX-TRF conjugate
and its effect on P-gp functionality and expression. In contrast
to the DOX-TRF conjugate, free DOX leads to a higher
expression of P-gp. The higher cytotoxicity of the DOX-
TRF conjugate may be associated with its lower affinity to
P-gp. Therefore, we suggest that a longer accumulation of the
DOX-TRF conjugate and its higher cytoplasmic concentration
Fig. 5 Analysis of P-gp expression in K562 cells resistant and
sensitive (K562/DOX) to doxorubicin. Results are presented as means ±
S.D. of four experiments. (∗) Significant differences between drug-treated
and control, untreated cells, p <0.05. (#) significant differences between
cells treated with free DOX or DOX-TRF, p <0.05
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may not lead to a higher ABCB1 gene expression level
and/or an increased P-gp mediated efflux.
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